Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement


See accompanying editorial on page 537

ABSTRACT

Purpose

The aim of International Myeloma Working Group was to develop practical recommendations for the use of magnetic resonance imaging (MRI) in multiple myeloma (MM).

Methods

An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations for the value of MRI based on data published through March 2014.

Recommendations

MRI has high sensitivity for the early detection of marrow infiltration by myeloma cells compared with other radiographic methods. Thus, MRI detects bone involvement in patients with myeloma much earlier than the myeloma-related bone destruction, with no radiation exposure. It is the gold standard for the imaging of axial skeleton, for the evaluation of painful lesions, and for distinguishing benign versus malignant osteoporotic vertebral fractures. MRI has the ability to detect spinal cord or nerve compression and presence of soft tissue masses, and it is recommended for the workup of solitary bone plasmacytoma. Regarding smoldering or asymptomatic myeloma, all patients should undergo whole-body MRI (WB-MRI; or spine and pelvic MRI if WB-MRI is not available), and if they have one focal lesion of a diameter > 5 mm, they should be considered to have symptomatic disease that requires therapy. In cases of equivocal small lesions, a second MRI should be performed after 3 to 6 months, and if there is progression on MRI, the patient should be treated as having symptomatic myeloma.

MRI at diagnosis of symptomatic patients and after treatment (mainly after autologous stem-cell transplantation) provides prognostic information; however, to date, this does not change treatment selection.

INTRODUCTION

Bone disease, characterized by the presence of osteolytic lesions, bone fractures, or osteoporosis, is a significant cause of morbidity and mortality in multiple myeloma (MM). Therefore, the guidelines of the International Myeloma Working Group (IMWG) suggest that the presence of even asymptomatic bone disease on conventional radiography is a criterion of symptomatic MM that requires treatment.1

In 2009, the IMWG indicated that whole-body (WB) x-ray (WBXR) remains the gold standard for the evaluation of MM-related bone disease.2 However, the detection limit of WBXR is low; to detect an osteolytic lesion by WBXR, a proportion of at least 30% to 50% of the trabecular bone has to be resorbed.1 Moreover, WBXR is not a suitable technique for the diagnosis of myeloma-related osteoporosis, has low visualization of the spine and pelvis, and cannot accurately depict the cause of painful lesions in patients with MM. In previous recommendations, the IMWG supported the implementation of magnetic resonance imaging (MRI) in the absence of osteolytic lesions on WBXR.3 However, the IMWG did not suggest the use of MRI for the definition of symptomatic myeloma. Thus, to date, a patient with focal lesions on MRI but with no lytic lesions on WBXR and with no other CRAB (hypercalcemia, renal failure, anemia, and bone disease)
criteria is considered to have smoldering or asymptomatic myeloma (SMM), and follow-up with no treatment is recommended. Several novel data stress the value of MRI in this setting, and we suggest that the current treatment practice be changed for these patients. Our aim was to produce useful recommendations for the use of MRI in everyday clinical practice for the management of patients with myeloma and introduce novel MRI criteria for the definition of SMM.

**METHODS**

An interdisciplinary panel of experts on myeloma bone disease and MRI performance in patients with myeloma developed the recommendations based on evidence of published clinical or observational studies, meta-analyses, and systematic reviews through March 2014. Expert consensus was used to propose recommendations in the absence of sufficiently published data. Levels of evidence and grades of recommendations were used according to established criteria (Table 1). The statement was drafted and circulated among all panel members, followed by subsequent rounds of revision until consensus was achieved.

**MRI TECHNIQUES FOR MYELOMA**

Several MRI techniques have been developed for the assessment of bone marrow involvement in MM: T1 weighted, T2 weighted with fat suppression, short time inversion recovery, and gadolinium T1 weighted with fat suppression. Myeloma lesions typically show a low signal intensity on T1-weighted images, a high signal intensity on T2-weighted images, and enhancement on gadolinium-enhanced images. Myeloma lesions typically show a low signal intensity on T1-weighted images, a high signal intensity on T2-weighted images, and enhancement on gadolinium-enhanced images. The dynamic contrast-enhanced MRI (DCE-MRI) is another MRI technique in which the distribution of a contrast agent inside and outside the blood vessels is assessed by computer-based analysis of repeated images over time. The analysis provides data for blood volume and vessel permeability for the assessment of microcirculation. More importantly, in patients with MM, DCE-MRI measurements have been correlated with marrow angiogenesis and MVD as well as with angiogenic response to therapy. Regarding DCE-MRI sampling rate and model, there are two pharmacokinetic models (proposed by Brix and Toots) that have been applied in the literature. However, a comparison of these models demonstrated that the Brix model is slightly more robust. Because DCE-MRI has not been established in clinical routine, no definite sequence can be recommended.

Positron emission tomography (PET) in combination with MRI is a novel and promising new methodology in which PET detects active focal lesions, while MRI shows the location of the lesions and provides information on myeloma cell infiltration of the bone marrow. Especially in patients who reach a complete remission (CR), this technique might be able to localize residual sites of disease activity and therefore may help to guide treatment in the future.

---

**Table 1. Levels of Evidence and Grades of Recommendations**

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence obtained from meta-analysis of multiple well-designed, controlled studies; randomized trials with low false-positive and low false-negative errors (high power)</td>
</tr>
<tr>
<td>II</td>
<td>Evidence obtained from at least one well-designed experimental study; randomized trials with high false-positive and/or false-negative errors (low power)</td>
</tr>
<tr>
<td>III</td>
<td>Evidence obtained from well-designed, quasi-experimental studies (e.g., nonrandomized, controlled single-group, pre-post, cohort, time, or matched case-control studies)</td>
</tr>
<tr>
<td>IV</td>
<td>Evidence from well-designed, nonexperimental studies (e.g., comparative and correlational descriptive and case studies)</td>
</tr>
<tr>
<td>V</td>
<td>Evidence from case reports and clinical examples</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Evidence of type I or consistent findings from multiple studies of types II, III, or IV</td>
</tr>
<tr>
<td>B</td>
<td>Evidence of type II, III, or IV; findings are generally consistent</td>
</tr>
<tr>
<td>C</td>
<td>Evidence of type II, III, or IV; findings are inconsistent</td>
</tr>
<tr>
<td>D</td>
<td>Little or no systematic empiric evidence</td>
</tr>
</tbody>
</table>

**Table 2. Minimum Technical Requirements for Use of MRI in Patients With Myeloma**

<table>
<thead>
<tr>
<th>Type</th>
<th>Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coil</td>
<td>Target volume adapted surface-reception coil system</td>
</tr>
<tr>
<td>Examination volume</td>
<td>Whole spine and pelvic MRI (if WB-MRI is not available)</td>
</tr>
<tr>
<td>Orientation</td>
<td>Sagittal axial for spine, axial coronal for pelvis</td>
</tr>
<tr>
<td>Parameter</td>
<td>Slice thickness 4 mm (definitely not &gt; 5 mm)</td>
</tr>
<tr>
<td>Weighting</td>
<td>T1, T2</td>
</tr>
<tr>
<td>Sequences</td>
<td>Sagittal T1 TSE, sagittal or coronal TIRM (STIR), axial T1 and T2, TSE, chemical shift, and T1 post contrast</td>
</tr>
</tbody>
</table>

Abbreviations: MRI, magnetic resonance imaging; STIR, short time inversion recovery; TIRM, turbo inversion recovery magnitude; TSE, turbo spin echo; WB, whole body.
Five MRI patterns of marrow involvement in myeloma have been recognized: normal appearance of bone marrow, focal involvement (positive focal lesion is considered lesion of diameter ≥ 5 mm), homogeneous diffuse infiltration, combined diffuse and focal infiltration, and variegated or salt-and-pepper pattern with inhomogeneous bone marrow with interposition of fat islands.21,22 Low tumor burden is usually associated with a normal MRI pattern, but a high tumor burden is usually suspected when there is diffuse hypointense change on T1-weighted images, diffuse hyperintensity on T2-weighted images, and enhancement with gadolinium injection.23 In several studies, the percentage of symptomatic patients with each of the abnormal MRI bone marrow patterns has ranged from 18% to 50% for focal pattern, 25% to 43% for diffuse pattern, and 1% to 5% for variegated pattern.16 The Durie-Salmon PLUS system uses the number of focal lesions (from focal or combined focal and diffuse patterns) for the staging of a patient with myeloma rather than the diffuse or salt-and-pepper pattern.24

### MRI in Symptomatic Myeloma

#### MRI Versus Conventional Radiography and Other Imaging Techniques for Detection of Bone Involvement

MRI is more sensitive compared with WBXR for the detection of bone involvement in MM. In the largest series of patients published to date, MRI was compared with WBXR in 611 patients who received tandem autologous stem-cell transplantation (ASCT). MRI and WBXR detected focal and osteolytic lesions in 74% and 56% of the imaged anatomic sites, respectively. Furthermore, 52% of 267 patients with normal WBXR had focal lesions on MRI. More precisely, MRI detected more focal lesions compared with lytic lesions in WBXR in the spine (78% v 16%; *P < .001), pelvis (64% v 28%; *P < .001), and sternum (24% v 3%; *P < .001). WBXR had better performance than MRI in the ribs (10% v 43%; *P < .001) and long bones (37% v 48%; *P = .006) and equal results in the skull and shoulders.28 Similar results had been previously reported in smaller studies, where MRI was superior to WBXR for the detection of focal versus osteolytic lesions in the pelvis (75% v 46% of patients) and spine (76% v 42%), especially in the lumbar spine.29-30 A recent meta-analysis confirmed the superiority of MRI over WBXR regarding the detection of focal lesions and showed that MRI especially outscores WBXR in the axial skeleton but not in the ribs.31

Although it is clear that MRI can detect bone marrow focal lesions long before the development of osteolytic lesions on WBXR, other imaging techniques such as PET combined with computed tomography (CT), CT, or WB-CT detect more osteolytic lesions compared with WBXR.31 Do we have any evidence that MRI is superior to the other techniques in depicting bone involvement in myeloma? In a study with 41 patients with newly diagnosed MM, WB-MRI was found superior to WB-CT in detecting lesions in the skeleton.32 In a prospective study, Zamagni et al33 compared MRI of the spine and pelvis with WBXR versus PET-CT in 46 patients with MM at diagnosis. Although PET-CT was superior to WBXR in detecting lytic lesions in 46% of patients (19% had negative WBXR), it failed to reveal abnormal findings in 30% of patients who had abnormal MRI in the same areas, mainly of diffuse pattern. In that study, the combination of spine and pelvic MRI with PET-CT detected both medullary and extramedullary active myeloma sites in almost all patients (92%). Nevertheless, the Arkansas group was not able to confirm any superiority of MRI over PET-CT in the detection of more focal lesions in a large number of patients (n = 303) within the Total Therapy 3 protocols.34 Still, in 188 patients who had ≥ one focal lesion on MRI, MRI was superior to PET-CT regarding the detection of higher number of focal lesions (*P = .032). Furthermore, in this study, the presence of diffuse marrow pattern was not taken into consideration as an abnormal MRI finding.34 Compared with MIBI (sestamibi-technetium-99m) scan, WB-MRI detected more lesions in the vertebrae and long bones, produced similar results in the skull, and was inferior in the ribs.35 One important question on this point is the value of WB-MRI, which is not available everywhere, over MRI of the spine and pelvis. In 100 patients with MM or monoclonal gammopathy of undetermined significance (MGUS) who underwent WB-MRI, 10% presented with focal lesions merely in the extra-axial skeleton. These lesions would have been ignored if only MRI of the spine and pelvis had been performed.36

Other advantages of MRI over WBXR and CT include the discrimination of myeloma from normal marrow37,38; this finding can help in the differential diagnosis between myeloma and benign cause of a vertebral fracture. This is of extreme importance in cases of patients with a vertebral fracture and no other CRAB criteria or lytic lesions. MRI can also accurately illustrate the spinal cord and/or nerve root compression for surgical intervention or radiation therapy.24 Furthermore, the presence of soft tissue extension of MM and presence of extramedullary plasmacytomas, which develop in approximately 10% to 20% of patients during the course of their disease, can be precisely visualized by WB-MRI.38-40 MRI can also help in the better evaluation of avascular necrosis of the femoral head41 and presence of soft tissue amyloid deposits.42 Moreover, tumor load can be assessed and monitored by MRI, even in patients with nonsecretory or oligosecretory MM.43

#### Consensus Statement

MRI is the imaging gold-standard method for the detection of bone marrow involvement in MM (grade A). We stress that MRI detects bone marrow involvement and not bone destruction. MRI of the spine and pelvis can detect approximately 90% of focal lesions in MM, and thus, it can be used in cases where WB-MRI is not available (grade B). MRI is the procedure of choice to evaluate a painful lesion in patients with myeloma, mainly in the axial skeleton, and detect spinal cord compression (grade A). MRI is particularly useful in the evaluation of collapsed vertebrae, especially when myeloma is not active, where the possibility of osteoporotic fracture is high (grade B).

#### Prognostic Value of MRI

The prognostic significance of MRI findings in symptomatic myeloma has been evaluated. The largest study in the literature included 611 patients who received tandem ASCT-based protocols. Focal lesions detected by spinal MRI and not seen on WBXR independently correlated with overall survival (OS). Resolution of the focal lesions on MRI after treatment occurred in 60% of the patients who had superior survival. At disease progression after CR, MRI revealed new focal lesions in 26% of patients, enlargement of previous focal lesions in 28%, and both features in 15%.25 In a more recent analysis...
by the same group involving 429 patients, patients who had > seven focal lesions on MRI (n = 147) had a 73% probability of 3-year OS versus 86% for those who had zero to seven focal lesions (n = 235) and 81% for those who had diffuse pattern of marrow infiltration (n = 47; P = .04). PET-CT and WBXR also produced similar results in the univariable analysis. In the multivariable analysis, from the imaging variables, only the presence of > two osteolytic lesions on WBXR at diagnosis and presence of > three focal lesions on PET-CT 7 days after ASCT had independent prognostic value for inferior OS (P = .01 and .03, respectively). However, we have to mention the high percentage of patients (232 [54%] of 429) who had no detectable osteolytic lesions by WBXR and the absence of evaluation of diffuse MRI pattern in this study.44

The MRI pattern of marrow infiltration has also been reported to have prognostic significance in newly diagnosed patients with symptomatic disease.23,45,46 In the conventional chemotherapy era, Moulopoulos et al58 reported that the median OS of patients with newly diagnosed MM was 24 months if they had diffuse MRI pattern versus 51, 52, and 56 months for those with focal, variegated, and normal patterns, respectively (P = .001). This is possibly because diffuse MRI marrow pattern correlates with increased angiogenesis and advanced disease features.47,48 The same group also reported the prognostic value of MRI patterns in 228 patients with symptomatic MM who received first-line regimens based on novel agents. Patients with diffuse pattern had inferior survival compared with patients with other MRI patterns; moreover, the combination of diffuse MRI pattern, International Staging System stage III, and high-risk cytogenetics could identify a group of patients with poor survival (ie, median, 21 months; probability of 3-year OS, 35%).46 Another study in 126 patients with newly diagnosed symptomatic myeloma who underwent ASCT showed that the diffuse and variegated MRI patterns had an independent predictive value for disease progression (hazard ratio [HR], 1.922; P = .008).46 Finally, in patients with progressive or relapsed MM, an increased DCE-MRI signal indicated shorter progression-free survival, possibly because of its association with higher MVD.15

**Consensus Statement**

The number of MRI focal lesions (> seven; grade A) and presence of diffuse pattern (grade B) correlate with inferior survival. Prospective clinical studies are needed to define if these patients have to be treated in a different or more aggressive way.

**MRI and Response to Antimyeloma Therapy**

An interesting finding is that a change in MRI pattern correlates with response to therapy. Moulopoulos et al49 first reported in the era of conventional chemotherapy that CR is characterized by complete resolution of the preceding marrow abnormality, whereas partial response is characterized by changeover of diffuse pattern to variegated or focal pattern. In a retrospective study that was conducted in the era of novel agents, response to treatment was compared with changes in infiltration pattern on WB-MRI before and after ASCT (n = 100). There was a strong correlation between response to antimyeloma therapies and changes in both diffuse (P = .004) and focal (P = .01) MRI patterns. Furthermore, the number of focal lesions on second MRI was of prognostic significance for OS (P = .001).50 Another study in 33 patients who underwent ASCT showed that WB-MRI data demonstrated progressive disease in 10 patients (30%) and response to high-dose therapy in 23 (70%). Eight (80%) of the 10 patients with progressive disease revealed intramedullary lesions, and two patients (20%) had intra- and extramedullary lesions. WB-MRI had a sensitivity of 64%, specificity of 86%, positive predictive value of 70%, negative predictive value of 83%, and accuracy of 79% for detection of remission.51 This study supports that one of the disadvantages of MRI is that it often provides false-positive results because of persistent nonviable lesions. Thus, PET-CT might be more suitable than MRI for determination of remission status.52 Indeed, in a large study of 191 patients, PET-CT revealed faster change of imaging findings than MRI in patients who responded to therapy.53 It seems that PET-CT normalization after treatment can offer more information compared with MRI for the better definition of CR.54

To improve the results of MRI for the most accurate detection of remission, DW-MRI has been recently used. In a first preliminary report, ADC values in active myeloma were significantly higher than in marrow in remission.55 Furthermore, the mean ADC increased in 95% of responding patients and decreased in all non-responders (n = 5; P = .002). An increase of ADC by 3.3% was associated with response, having a sensitivity of 90% and specificity of 100%. Furthermore, there was a negative correlation between changes of ADC and changes of biochemical markers of response (r = −0.614; P = .001).56 Large prospective clinical studies are definitely justified by these results.

**Consensus Statement**

MRI might help in the better definition of CR (grade D; panel consensus). Nevertheless, the high number of false-positive results suggests that its combination with methods that reveal active lesions (ie, PET-MRI) or another imaging method, such as PET-CT, might be of more value in this setting. Thus, the systematic performance of MRI for the follow-up of patients, before or after different therapies, in the absence of clinical indications is not recommended. Novel clinical studies have to include MRI for the response evaluation in an effort to clarify the role of MRI in this important field of myeloma therapy.

The presence of lytic lesions by WBXR is included in the definition of symptomatic myeloma, based on studies showing that patients with ≥ one lytic lesion on WBXR have a median time to progression (TTP) of 10 months.57 However, in patients with no osteolytic lesions on WBXR, MRI reveals abnormal marrow appearance in 20% to 50%,22,23,38-60; these patients are at higher risk for progression. Moulopoulos et al58 reported that patients with SMM and abnormal MRI studies required therapy after a median of 16 months versus 43 months for those with normal MRI (P < .01). Hillengass et al59 evaluated WB-MRI in 149 patients with SMM. Focal lesions were detected in 42 patients (28%), while > one focal lesion was present in 23 patients (15%) who had high risk of progression (HR, 4.05; P < .001). The median TTP was 13 months, and the progression rate at 2 years was 70%. On multivariable analysis, presence of > one focal lesion remained a significant predictor of progression after adjusting for other risk factors, including bone marrow plasmacytosis, serum and urine M protein levels, and suppression of uninvolved immunoglobulins. In the same study, diffuse marrow infiltration on MRI was also associated with increased risk for progression (HR, 3.5; P < .001). Kasritis et al60 also showed in a study of 98 patients with SMM that abnormal marrow pattern on MRI of the spine, which was present in...
21% of patients, was associated with high risk of progression, with a median TTP to symptomatic myeloma of 15 months ($P = .001$).

The identification of patients with SMM who are at high risk for progression is of great importance, because these patients may benefit from immediate therapy. A recent randomized study from the Spanish Myeloma Study Group compared the combination of lenalidomide plus low-dose dexamethasone (Rd) versus observation in patients with high-risk SMM (MRI was not used for defining high-risk SMM). TTP was significantly longer with Rd compared with observation (median, not reached vs 21 months, respectively; $P < .001$). More importantly, Rd offered OS advantage (probability of 3-year survival, 94% vs 80%, respectively; $P = .03$).61

An important issue is whether patients who have $\geq$ two small focal lesions (< 5 mm) should be considered as having symptomatic myeloma and how to manage them. Recently, the Heidelberg group analyzed data of 63 patients with SMM who had $\geq$ two WB-MRIs performed for follow-up before progression to symptomatic disease. The definition of radiologic progression according to MRI findings included one of the following: development of a new focal lesion, increase of the diameter of an existing focal lesion, or detection of novel or progressive diffuse MRI pattern. The second MRI was performed 3 to 6 months after the performance of the first MRI. Evaluation of response according to IMWG criteria was also performed. Progressive disease according to MRI was observed in approximately 50% of patients, whereas 40% of patients developed symptomatic MM based on the CRAB criteria. In the multivariable analysis, progressive disease according to MRI was an independent prognostic factor for progression. Patients with stable MRI findings had no higher risk of progression, even when focal lesions were present on the initial MRI.62 Prospective clinical trials should be conducted to confirm these findings.

**Consensus Statement**

We recommend that patients with $>\text{one unequivocal focal lesion (diameter } \geq 5 \text{ mm)}$ should be considered to have symptomatic myeloma that requires therapy (grade B). Patients with equivocal focal lesions should repeat the MRI after 3 to 6 months, and in cases of MRI progression, patients should be considered as symptomatic patients who need therapy (grade C; panel consensus). The biopsy of such lesions should be encouraged. Regarding diffuse MRI marrow pattern, we need additional studies before its incorporation into the definition of symptomatic myeloma.

**MRI Findings in MGUS**

MGUS by definition is characterized by the absence of osteolytic lesions. However, patients with MGUS have higher incidences of osteoporosis and vertebral fractures compared with the normal population.53,64 In a small study that included 37 patients with MGUS or SMM, MRI abnormalities were detected in 20%. These patients had a higher TTP to symptomatic myeloma compared with patients with a normal MRI who did not experience progression after a median follow-up of 30 months.65 A prospective study involving 331 patients with MGUS or SMM revealed that the detection of multiple (> one) focal lesions by MRI conferred an increased risk of progression.66 In another large study, which included only patients with MGUS (n = 137) who underwent WB-MRI at diagnosis, a focal infiltration pattern was detected in 23%. Independent prognostic factors for progression to symptomatic myeloma included the presence and number of focal lesions and value of M-protein.67

**MRI and Solitary Bone Plasmacytoma**

The diagnosis of solitary plasmacytoma of the bone (SBP) includes the presence of a solitary bone lesion, with a confirmed infiltration by plasma cells on biopsy of the lesion, absence of clonal plasma cells on the trephine bone marrow biopsy, and no CRAB criteria met. Although definitive radiotherapy usually eradicates the local disease, a majority of patients will develop MM because of the growth of previously occult lesions not detected by WBXR.59,60 Moulopoulos et al58 reported that spinal MRI revealed additional focal lesions in four of 12 patients with SBP. After treatment with radiotherapy to the painful lesion, three patients developed systemic disease within 18 months from diagnosis. Furthermore, Liebross et al62 observed that among patients with SBP with spinal disease, seven of eight staged by WBXR...
alone developed MM, compared with only one of seven patients who also underwent spinal MRI.

**Consensus Statement**

MRI should be part of the staging procedures in patients with SBP to better assess the extent of the local tumor and reveal occult lesions elsewhere (grade A).

**DISCUSSION**

In summary, MRI describes the pattern of myelomatous infiltration of the bone marrow and is the procedure of choice for the evaluation of painful lesions in patients with myeloma for the detection of spinal cord compression and differentiation of malignant from nonmalignant vertebral fractures. MRI provides significant prognostic information in patients with symptomatic disease and may be found useful in the better definition of CR. More importantly, MRI can reclassify patients with SMM to symptomatic MM, and patients with > one unequivocal focal lesion (diameter of > 5 mm) should be considered as having symptomatic myeloma that requires therapy. Finally, MRI is part of the staging workup of SBP. A summary of the recommendations is listed in Table 3.

**REFERENCES**

31. Regelink JC, Minnema MC, Terpos E, et al: Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related
42. Syed IS, Gluckner JF, Feng D, et al: Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovas Imaging 3:155-164, 2010

Affiliations
Meletios A. Dimopoulos and Evangelos Terpos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; Jens Hillengass and Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany; Saad Usmani, Carolinas Healthcare System, Charlotte, NC; Elena Zamagni and Michele Cavo, Bologna University School of Medicine, Bologna; Antonio Palumbo, S. Giovanni Battista Hospital, University of Turin, Turin, Italy; Suzanne Lenzsch, Columbia University College of Physicians and Surgeons, New York, NY; Faith E. Davies, Institute of Cancer Research, Sutton, United Kingdom; Noopur Raje, Massachusetts General Hospital Cancer Center; Kenneth Anderson, Dana-Farber Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA; Orhan Sezer, Memorial Sisli Hospital, Istanbul, Turkey; Sonja Zweegman, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, the Netherlands; Jatin Shah, MD Anderson Cancer Center, Houston, TX; Ashraf Badros, University of Maryland Medical Center, Baltimore, MD; Kazuyuki Shimizu, Tokai Central Hospital, Kakamigahara, Japan; Philippe Moreau, University Hospital Hôtel-Dieu,
Nantes, France; Chor-Sang Chim, Queen Mary Hospital, University of Hong Kong, Hong Kong, Special Administrative Region; Jian Hou, Changzheng Hospital, Second Military Medical University, Shanghai, People’s Republic of China; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Artur Jurczyszyn, University Hospital, Krakow, Poland; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Bart Barlogie, University of Arkansas for Medical Sciences, Little Rock, AR; G. David Roodman, Indiana University School of Medicine, Indianapolis, IN; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; and Brian G.M. Durie, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA.

---

**GLOSSARY TERMS**

**dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI):** a magnetic resonance imaging acquisition strategy involving multiple scans over a set volume during injection of a magnetic resonance contrast agent.

**microvessel density (MVD):** a quantification technique used to assess the number of vessels in a particular tumor specimen using immunohistochemical stains for endothelial markers. High MVD has been found to be associated with poor prognosis in patients with solid tumors.

---

**Not an ASCO Member? Subscribe to Journal of Oncology Practice**

*Journal of Oncology Practice (JOP)* is ASCO’s bimonthly forum for providing its subscribers with information, news, and tools to enhance practice efficiency and promote a high standard of quality for patient care.

Every issue of JOP includes important features on cancer policy issues and their practical effect on cancer care, methods for enhancing the quality of patient care, and tools for improving practice management.

Whether practitioners are in an office or hospital setting, a community or academic environment, *JOP* provides practical information and advice that oncologists and other oncology professionals can apply immediately to their practices. Key features include:

- Articles for all members of the practice—physicians, nurses, and administrators
- Timely and relevant information to help practices succeed
- Focus on improving practice efficiency and quality of care
- Coverage of legal, financial, technology, and personnel issues

Subscribe today at [jop.ascopubs.org](http://jop.ascopubs.org).
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

Meletios A. Dimopoulos
Consulting or Advisory Role: Ortho Biotech (Inst), Celgene (Inst), Onyx Pharmaceuticals (Inst)

Jens Hillengass
Honoraria: Celgene, Janssen-Cilag, Medtronic
Travel, Accommodations, Expenses: Celgene, Janssen-Cilag, Medtronic

Saad Usmani
Honoraria: Celgene, Onyx Pharmaceuticals, sanofi-aventis, Millennium Pharmaceuticals
Consulting or Advisory Role: Celgene, Onyx Pharmaceuticals, sanofi-aventis, Millennium Pharmaceuticals
Speakers’ Bureau: Celgene, Onyx Pharmaceuticals, Millennium Pharmaceuticals
Research Funding: Celgene, Onyx Pharmaceuticals, Janssen-Cilag, Array BioPharma, Pharmacyclics

Elena Zamagni
No relationship to disclose

Suzanne Lentzsch
Consulting or Advisory Role: Celgene, Bristol-Myers Squibb, Millennium Pharmaceuticals, Janssen
Speakers’ Bureau: Axiom
Research Funding: Celgene

Faith E. Davies
Honoraria: Celgene, Janssen-Cilag
Consulting or Advisory Role: Millennium Pharmaceuticals, Onyx Pharmaceuticals, Celgene, Janssen-Cilag

Noopur Raje
Consulting or Advisory Role: Celgene, Millennium Pharmaceuticals, Amgen, Novartis
Research Funding: Eli Lilly, Acetylon Pharmaceuticals

Orhan Sezer
Honoraria: Celgene, Janssen-Cilag
Consulting or Advisory Role: Celgene, Janssen-Cilag

Sonja Zweegman
Consulting or Advisory Role: Celgene (Inst), Janssen-Cilag (Inst), Millennium Pharmaceuticals (Inst)
Research Funding: Celgene (Inst), Janssen-Cilag (Inst), Millennium Pharmaceuticals (Inst)

Jatin Shah
Consulting or Advisory Role: Celgene, Novartis, Millennium Pharmaceuticals, Onyx Pharmaceuticals, sanofi-aventis, Array BioPharma
Research Funding: Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, Array BioPharma

Ashraf Badros
No relationship to disclose

Kazuyuki Shimizu
Consulting or Advisory Role: Daiichi Sankyo
Expert Testimony: Amgen

Philippe Moreau
No relationship to disclose

Chor-Sang Chin
Honoraria: Janssen Oncology, Novartis
Consulting or Advisory Role: Novartis
Speakers’ Bureau: Janssen Oncology
Travel, Accommodations, Expenses: Janssen Oncology, Novartis

Juan José Lahuerta
Consulting or Advisory Role: Celgene, Janssen-Cilag
Travel, Accommodations, Expenses: Celgene

Jian Hou
No relationship to disclose

Artur Jurczyszyn
Travel, Accommodations, Expenses: Celgene, Teva

Hartmut Goldschmidt
Honoraria: Janssen Pharmaceuticals, Celgene, Novartis, Chugai Pharmaceutical, Onyx Pharmaceuticals, Millennium Pharmaceuticals
Consulting or Advisory Role: Janssen Pharmaceuticals (Inst), Celgene (Inst), Novartis (Inst), Onyx Pharmaceuticals (Inst), Millennium Pharmaceuticals (Inst)
Research Funding: Janssen Pharmaceuticals (Inst), Celgene (Inst), Novartis (Inst), Chugai Pharmaceutical (Inst)

Pieter Sonneveld
Consulting or Advisory Role: Celgene (Inst), Onyx Pharmaceuticals (Inst), Janssen-Cilag (Inst), Millennium Pharmaceuticals (Inst), Novartis
Research Funding: Celgene (Inst), Onyx Pharmaceuticals (Inst), Janssen-Cilag (Inst)

Antonio Palumbo
Honoraria: Amgen, Bristol-Myers Squibb, Array BioPharma, Genmab, Celgene, Janssen-Cilag, Millennium Pharmaceuticals, BiPar/sanofi-aventis, Onyx Pharmaceuticals
Consulting or Advisory Role: Bristol-Myers Squibb, Amgen, Genmab, Celgene, Janssen-Cilag, Millennium Pharmaceuticals, Onyx Pharmaceuticals

Heinz Ludwig
Consulting or Advisory Role: Celgene (Inst), Janssen-Cilag (Inst), Onyx Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst)
Speakers’ Bureau: Celgene, Janssen-Cilag
Research Funding: Takeda Pharmaceuticals (Inst)
Travel, Accommodations, Expenses: Sandoz

Michele Cavo
Honoraria: Janssen-Cilag, Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Bristol-Myers Squibb
Consulting or Advisory Role: Janssen-Cilag, Celgene, Millennium Pharmaceuticals
Speakers’ Bureau: Janssen-Cilag, Celgene

Bart Barlogie
Consulting or Advisory Role: Celgene, Millennium Pharmaceuticals
Research Funding: Celgene
Patents, Royalties, Other Intellectual Property: Myeloma Health
Travel, Accommodations, Expenses: Celgene, Multiple Myeloma Research Foundation, Dana-Farber Cancer Institute

Kenneth Anderson
No relationship to disclose
G. David Roodman
Consulting or Advisory Role: Amgen
Research Funding: Eli Lilly (Inst)

S. Vincent Rajkumar
No relationship to disclose

Brian G.M. Durie
No relationship to disclose

Evangelos Terpos
Honoraria: Celgene, Medtronic, Onyx Pharmaceuticals, Novartis, Janssen-Cilag, Amgen
Consulting or Advisory Role: Roche (Inst), Teva (Inst), Acetylon Pharmaceuticals (Inst), Amgen (Inst), Celgene (Inst)
Research Funding: Amgen (Inst), Janssen-Cilag (Inst)
Travel, Accommodations, Expenses: Janssen-Cilag, Genesis
Appendix

Members of the International Myeloma Working Group: Niels Abildgaard, Syddansk Universitet, Odense, Denmark; Rafat Abonour, Indiana University School of Medicine, Indianapolis, IN; Melissa Alsina, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Michel Attal, Purpan Hospital, Toulouse, France; Hervé Avet-Loiseau, University of Toulouse, Toulouse, France; Ashraf Badros, University of Maryland, Baltimore, MD; Bart Barlogie, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; Régis Bataille, Institut de Biologie, Nantes, France; Meral Beksaç, Ankara University, Ankara, Turkey; Andrew Belch, University of Alberta, Edmonton, Alberta, Canada; Dina Ben-Yehuda, Hadassah University Hospital, Hadassah, Israel; Bill Bensinger, Fred Hutchinson Cancer Center, Seattle, WA; P. Leif Bergsagel, Mayo Clinic Scottsdale, Scottsdale, AZ; Joan Bladé, Hospital Clinica, Barcelona, Spain; Mario Boccadoro, University of Torino, Torino, Italy; Jo Caers, Centre Hospitalier Universitaire de Liège, Belgium; Michele Cavo, Universita di Bologna, Bologna, Italy; Asher Chanan-Khan, Mayo Clinic, Jacksonville, FL; Wen Ming Chen, Beijing Chaoyang Hospital, Beijing, People’s Republic of China; Marta Chesi, Mayo Clinic Scottsdale, Scottsdale, AZ; J. Anthony Child, Leeds General Hospital, Leeds, United Kingdom; Chor Sang Chim, Queen Mary Hospital, Hong Kong, Special Administrative Region, People’s Republic of China; Wee-Joo Chng, National University Health System, Singapore, Singapore; Ray Comenzo, Tufts Medical School, Boston, MA; John Crowley, Cancer Research and Biostatistics, Seattle, WA; William Dalton, H. Lee Moffitt, Tampa, FL; Faith E. Davies, Royal Marsden Hospital, London, United Kingdom; Javier de la Rubia, Hospital Universitario La Fe, Valencia, Spain; Cármeno de Souza, Universidade de Campinas, Campinas, Brazil; Michel Delforge, University Hospital Gasthuisberg, Leuven, Belgium; Meletios A. Dimopoulos, University of Athens School of Medicine, Athens, Greece; Angela Dispenzieri, Mayo Clinic, Rochester, MN; Johannes Drach, University of Vienna, Vienna, Austria; Matthew Drake, Mayo Clinic, Rochester, MN; Juan Du, Changzhen Hospital, Shanghai, People’s Republic of China; Brian G.M. Durie, Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA; Hermann Einsele, Universitätsklinik Würzburg, Würzburg, Germany; Thierry Facon, Centre Hospitalier Regional Universitaire de Lille, Lille, France; Dorotea Fantl, Societatea Romana de Hematologie, Buenos Aires, Argentina; Jean-Paul Fermand, Hospital Saint-Louis, Paris, France; Carlos Fernández de Larrea, Hospital Clinic de Barcelona, Barcelona, Spain; Rafael Fonseca, Mayo Clinic Scottsdale, Scottsdale, AZ; Gösta Gahrton, Karolinska Institute for Medicine, Huddinge, Sweden; Ramón García-Sanz, University Hospital of Salamanca, Salamanca, Spain; Lauren Gardneret, Hospital Saint Antoine, Paris, France; Christina Gasparetto, Duke University Medical Center, Durham, NC; Morie Gertz, Mayo Clinic, Rochester, MN; Irene Ghobrial, Dana-Farber Cancer Institute, Boston, MA; John Gibson, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Peter Gimsing, University of Copenhagen, Copenhagen, Denmark; Sergio Giralt, Memorial Sloan-Kettering Cancer Center, New York, NY; Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany; Jingli Gu, The First Hospital, Sun Yat-Sen University, Guangdong, People’s Republic of China; Roman Hajek, University Hospital Ostrava and University Ostrava School of Medicine, Ostrava, Czech Republic; Izhar Hardan, Tel Aviv University, Tel Aviv, Israel; Parameswaran Hari, Medical College of Wisconsin, Milwaukee, WI; Hiroyuki Hata, Kumamoto University Hospital, Kumamoto, Japan; Yutaka Hattori, Keio University School of Medicine, Tokyo, Japan; Tom Heffner, Emory University, Atlanta, GA; Jens Hllengass, University of Heidelberg, Heidelberg, Germany; Joy Ho, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Antje Hoering, Cancer Research and Biostatistics, Seattle, WA; Jian Hou, Shanghai Chang Zheng Hospital, Shanghai, People’s Republic of China; Jeffrey Huang, National Taiwan University Hospital, Taipei, Taiwan; Vania Hungria, Clinica San Germano, Sao Paolo, Brazil; Shinsuke Ida, Nagoya City University Medical School, Nagoya, Japan; Peter Jacobs, Constantiaberg Medi-Clinic, Plumstead, South Africa; Sundar Jagannath, Mt. Sinai Cancer Institute, New York, NY; Andrzej J. Jakubowiak, University of Chicago, Chicago, IL; Hans Johnsen, Aalborg Hospital, Aalborg, Denmark; Douglas Joshua, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Artur Jurczyszyn, University Hospital, Krakow, Poland; Efstrathios Kastritis, University of Athens, Athens, Greece; Jonathan Kaufman, Emory Clinic, Atlanta, GA; Michio Kawano, Yamaguchi University, Ube, Japan; Neha Korde, National Institutes of Health, Bethesda, MD; Eva Kovacs, Cancer Immunology Research-Life, Birsfelden, Switzerland; Amrita Krishnan, City of Hope, Duarte, CA; Sigurdur Kristinsson, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; Nicolaus Kröger, University Hospital Hamburg, Hamburg, Germany; Shaji Kumar, Mayo Clinic, Rochester, MN; Robert A. Kyle, Mayo Clinic, Rochester, MN; Chor Sang Chim, Queen Mary Hospital, London, United Kingdom; Martha Lacy, Mayo Clinic, Rochester, MN; Juan José Lahuerta, Grupo Español de Mieloma, Hospital Universitario 12 de Octubre, Madrid, Spain; Olá Landgren, Memorial Sloan-Kettering Cancer Center, New York, NY; Alessandra LaRocca, Divisione Universitaria di Ematologia, Torino, Italy; Jacob Laubach, Dana-Farber Cancer Institute, Boston, MA; Fernando Leal da Costa, Instituto Portugues De Oncologia, Lisbon, Portugal; Jae-Hoon Lee, Gachon University Hospital, Incheon, Korea; Merav Leiba, Sheba Medical Center, Tel Hashomer, Israel; Xavier LeLeu, Hospital Huriez, Centre Hospitalier R[acte]regional Universitaire, Lille, France; Suzanne Lentsch, Columbia University, New York, NY; Nelson Leung, Mayo Clinic, Rochester, MN; Henk Lokhorst, University Medical Center Utrecht, Utrecht, the Netherlands; Sagar Lonial, Emory University Medical School, Atlanta, GA; Jin Lu, People’s Hospital, Beijing University, Beijing, People’s Republic of China; Heinz Ludwig, Wilhelmenspital der Stadt Wien, Vienna, Austria; Anuj Mahindra, University of California at San Francisco, San Francisco, CA; Angelo Maiolini, Rua fonte da Saudade, Rio de Janeiro, Brazil; Maria-Marivi Mateos, University Hospital of Salamanca–Instituto de Investigación Biomédica de Salamanca (IBSAL), Instituto de Biología Molecular y Celular del Cancer (IBMCC; Universidad de Salamanca [USAL] –Centro Superior de Investigaciones Científicas [CSIC]), Salamanca, Spain; Amitabha Mazumder, New York University Comprehensive Cancer Center, New York, NY; Philip McCarthy, Roswell Park Cancer Center, Buffalo, NY; Jayesh Mehta, Northwestern...
University, Chicago, IL; Ulf-Henrik Mellqvist, Sahlgrenska University Hospital, Gothenburg, Sweden; Giampaolo Merlini, University of Pavia, Pavia, Italy; Joseph Mikhael, Mayo Clinic Scottsdale, Scottsdale, AZ; Philippe Moreau, University Hospital, Nantes, France; Gareth Morgan, Royal Marsden Hospital, London, United Kingdom; Nikhil Munshi, Dana-Farber Cancer Institute, Boston, MA; Hareth Nahi, Karolinska University Hospital, Stockholm, Sweden; Weerasak Nawarawong, Chiang Mai University, Chiang Mai, Thailand; Ruben Nieszizky, Weill Cornell Medical College, New York, NY; Amara Nouel, Hospital Rutz y Paez, Bolivar, Venezuela; Yana Novis, Hospital Sirio Libanês, Bela Vista, Brazil; Enrique Ocío, University Hospital of Salamanca–IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain; Alberto Orfao, University Hospital of Salamanca–IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain; Robert Orlowski, MD Anderson Cancer Center, Houston, TX; Bruno Paiva, Clinica Universitaria de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain; Antonio Palumbo, University of Torino, Torino, Italy; Santiago Pavlovsky, Fundaleu, Buenos Aires, Argentina; Linda Pilarski, University of Alberta, Edmonton, Alberta, Canada; Raymond Powles, Parkside Cancer Centre, London, United Kingdom; Noopur Raje, Massachusetts General Hospital, Boston, MA; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Donna Reece, Princess Margaret Hospital, Toronto, Ontario, Canada; Anthony Reiman, Saint John Regional Hospital, Saint John, New Brunswick, Canada; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Angelina Rodriguez Morales, Bonco Metro Politano de Sangre, Caracas, Venezuela; Kenneth R. Romeril, Wellington Hospital, Wellington, New Zealand; David Roodman, Indiana University, Indianapolis, IN; Laura Rosiñoł, Hospital Clinic, Barcelona, Spain; Murielle Rousseau, University of Toulouse, Toulouse, France; Stephen Russell, Mayo Clinic, Rochester, MN; Jesús San Miguel, Clinica Universitaria de Navarra, CIMA, Pamplona, Spain; Rik Schots, Universitair Ziekenhuis Brussel, Brussels, Belgium; Sabina Sevcikova, Masaryk University, Brno, Czech Republic; Orhan Sezer, Memorial Sisli Hastanesi, Istanbul, Turkey; Jatin J. Shah, MD Anderson Cancer Institute, Houston, TX; Kazuyuki Shimizu, Tokai Central Hospital, Kakamigahara, Japan; Chaim Shustik, McGill University, Montreal, Quebec, Canada; David Siegel, Hackensack University Medical Center, Hackensack, NJ; Seema Singhal, Northwestern University, Chicago, IL; Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, the Netherlands; Andrew Spencer, Alfred Hospital, Melbourne, Victoria, Australia; Edward Stadtmauer, University of Pennsylvania, Philadelphia, PA; Keith Stewart, Mayo Clinic Scottsdale, Scottsdale, AZ; Daryl Tan, Singapore General Hospital, Singapore, Singapore; Evangelos Terpos, University of Athens School of Medicine, Athens, Greece; Patrizia Tosi, Italian Cooperative Group, Istituto di Ematologia Seragnoli, Bologna, Italy; Guido Tricot, University of Iowa Hospital and Clinics, Iowa City, IA; Ingemar Turesson, Skane University Hospital, Malmö, Sweden; Saad Usmani, Levine Cancer Institute/Carolina’s Healthcare System, Charlotte, NC; Ben Van Camp, Vrije Universiteit Brussel, Brussels, Belgium; Brian Van Ness, University of Minnesota, Minneapolis, MN; Ivan Van Riet, Vrije Universiteit Brussel (VUB), Brussels, Belgium; Isabelle Vande Broek, VUB, Brussels, Belgium; Karin Vanderkerken, VUB, Brussels, Belgium; Robert Vesco, Cedars-Sinai Cancer Center, Los Angeles, CA; David Vesole, Hackensack University Medical Center, Hackensack, NJ; Peter Voorhees, University of North Carolina, Chapel Hill, NC; Anders Waage, University Hospital, Trondheim, Norway; Michael Wang, MD Anderson Cancer Center, Houston, TX; Donna Weber, MD Anderson Cancer Center, Houston, TX; Jan Westin, Sahlgrenska University Hospital, Gothenburg, Sweden; Keith Wheatley, University of Birmingham, Birmingham, United Kingdom; Elena Zamagni, University of Bologna, Bologna, Italy; Jeffrey Zonder, Karmanos Cancer Institute, Detroit, MI; and Sonja Zweegman, VU University Medical Center, Amsterdam, the Netherlands.